We believe biophysics-based techniques can play a key role in the success of any drug discovery project.
Biophysical assays are especially valuable when no historic data to suggest the structure of chemical matter is available.
Charnwood Discovery has brought together a suite of cutting-edge, market-leading biophysical technologies to provide insights into molecular interactions in many different project settings.
Biophysical assays can dovetail well with our integrated drug discovery projects – working in tandem with biochemical or cell biology-based assays to quickly return binding data to our ADME/DMPK and medicinal chemistry colleagues. Equally, our biophysics suite can be used for standalone projects to definitively measure and characterize the binding of one molecule to another.
Our biophysics suite can be applied to projects with a wide variety of molecular characteristics – from protein-protein interactions, to peptides and large lead-like or natural product compounds, all the way down to fragment screening, either as singleton spot-testing or else fragment cocktails.
The flexibility of our biophysics suite means it can be applied to both standalone and fully integrated projects to answer key questions such as:
- Do your molecules bind their target?
- How do they bind?
- Where do they bind?
In addition, our powerful technologies can drive the start of a project: initial hit finding, fragment-based drug discovery, high-throughput work.
It will also deliver at later stages of a project: lead optimization, affinity determination, kinetic analysis, thermodynamic analysis.
Find out more about the techniques we offer:
- Surface Plasmon Resonance (SPR)
- Fluorescence-based Thermal Shift Assay (FTSA)
- Isothermal Titration Calorimetry (ITC)
Contact our expert team who will discuss your needs with you and help you decide which of our biophysical techniques is best placed to progress your project.
Meet Our Expert
Principal Research Scientist, Patrick McIntyre, is our lead biophysical techniques expert. Bringing a wealth of academic and commercial experience, Patrick is able to add value to any project.
After graduating with a first class MChem degree from the University of Reading, Patrick went on to gain his PhD at the University of Leicester where his project focused on fragment-based drug discovery of allosteric kinase inhibitors.
Multiple screening formats were used to successfully identify a number of allosteric fragment hits against a target and these hits were validated using a number of orthogonal biophysical and biochemical techniques.
Since his PhD, Patrick has spent five years in an industrial CRO environment, focusing on biophysical assay development and screening.
Connect with Patrick on LinkedIn.
